Q3 2024 Earnings Estimate for Biohaven Ltd. (NYSE:BHVN) Issued By Leerink Partnrs

Biohaven Ltd. (NYSE:BHVN) – Equities researchers at Leerink Partnrs reduced their Q3 2024 EPS estimates for Biohaven in a research report issued on Monday, September 23rd. Leerink Partnrs analyst M. Goodman now forecasts that the company will earn ($1.83) per share for the quarter, down from their previous forecast of ($1.80). The consensus estimate for Biohaven’s current full-year earnings is ($8.92) per share. Leerink Partnrs also issued estimates for Biohaven’s Q4 2024 earnings at ($1.88) EPS, FY2024 earnings at ($9.55) EPS, FY2025 earnings at ($6.60) EPS, FY2026 earnings at ($5.35) EPS, FY2027 earnings at ($2.80) EPS and FY2028 earnings at $0.55 EPS.

Biohaven (NYSE:BHVN) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($3.64) EPS for the quarter, missing analysts’ consensus estimates of ($1.72) by ($1.92).

Several other analysts also recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $59.00 price objective on shares of Biohaven in a report on Tuesday. William Blair upgraded shares of Biohaven to a “strong-buy” rating in a report on Friday, August 30th. Bank of America raised their price objective on shares of Biohaven from $52.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday. Royal Bank of Canada boosted their target price on shares of Biohaven from $59.00 to $68.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, UBS Group reduced their target price on Biohaven from $55.00 to $54.00 and set a “buy” rating for the company in a report on Tuesday, August 13th. Thirteen research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $60.92.

Biohaven Stock Down 0.4 %

Shares of Biohaven stock opened at $51.00 on Thursday. Biohaven has a 12-month low of $22.12 and a 12-month high of $62.21. The firm has a market capitalization of $4.50 billion, a PE ratio of -7.47 and a beta of 1.30. The stock’s fifty day moving average is $39.53 and its 200-day moving average is $40.75.

Insider Buying and Selling

In other news, Director Gregory Bailey bought 5,000 shares of the stock in a transaction on Tuesday, September 24th. The shares were purchased at an average price of $44.19 per share, for a total transaction of $220,950.00. Following the completion of the purchase, the director now directly owns 1,620,071 shares of the company’s stock, valued at approximately $71,590,937.49. The purchase was disclosed in a filing with the SEC, which is available through this link. In other Biohaven news, Director John W. Childs purchased 28,400 shares of the company’s stock in a transaction dated Thursday, July 18th. The shares were bought at an average price of $35.67 per share, for a total transaction of $1,013,028.00. Following the purchase, the director now directly owns 2,339,741 shares in the company, valued at approximately $83,458,561.47. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gregory Bailey purchased 5,000 shares of the business’s stock in a transaction dated Tuesday, September 24th. The shares were acquired at an average price of $44.19 per share, for a total transaction of $220,950.00. Following the acquisition, the director now directly owns 1,620,071 shares in the company, valued at approximately $71,590,937.49. The disclosure for this purchase can be found here. 16.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Biohaven

Hedge funds have recently bought and sold shares of the business. Algert Global LLC lifted its position in shares of Biohaven by 5.9% in the second quarter. Algert Global LLC now owns 7,402 shares of the company’s stock worth $257,000 after buying an additional 412 shares during the last quarter. Hsbc Holdings PLC lifted its holdings in Biohaven by 6.1% in the 2nd quarter. Hsbc Holdings PLC now owns 8,291 shares of the company’s stock worth $286,000 after purchasing an additional 480 shares during the last quarter. Canton Hathaway LLC boosted its position in Biohaven by 2.3% during the second quarter. Canton Hathaway LLC now owns 21,850 shares of the company’s stock worth $758,000 after purchasing an additional 500 shares during the period. Arizona State Retirement System grew its holdings in Biohaven by 3.7% during the second quarter. Arizona State Retirement System now owns 20,575 shares of the company’s stock valued at $714,000 after purchasing an additional 730 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Biohaven by 4.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,431 shares of the company’s stock valued at $605,000 after purchasing an additional 778 shares during the period. 88.78% of the stock is owned by institutional investors and hedge funds.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.